GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (WBO:GLPG) » Definitions » Cyclically Adjusted Price-to-FCF

Galapagos NV (WBO:GLPG) Cyclically Adjusted Price-to-FCF : 13.42 (As of Jun. 05, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Galapagos NV Cyclically Adjusted Price-to-FCF?

As of today (2025-06-05), Galapagos NV's current share price is €25.36. Galapagos NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €1.89. Galapagos NV's Cyclically Adjusted Price-to-FCF for today is 13.42.

The historical rank and industry rank for Galapagos NV's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

WBO:GLPG' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 7.73   Med: 11.58   Max: 21.6
Current: 13.35

During the past years, Galapagos NV's highest Cyclically Adjusted Price-to-FCF was 21.60. The lowest was 7.73. And the median was 11.58.

WBO:GLPG's Cyclically Adjusted Price-to-FCF is ranked better than
90.29% of 103 companies
in the Biotechnology industry
Industry Median: 49.09 vs WBO:GLPG: 13.35

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Galapagos NV's adjusted free cash flow per share data for the three months ended in Mar. 2025 was €-0.666. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €1.89 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted Price-to-FCF Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.78 9.96 11.20 14.22 14.75

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.51 11.15 13.44 14.75 12.20

Competitive Comparison of Galapagos NV's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted Price-to-FCF falls into.


;
;

Galapagos NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Galapagos NV's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=25.36/1.89
=13.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Galapagos NV's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.666/134.3475*134.3475
=-0.666

Current CPI (Mar. 2025) = 134.3475.

Galapagos NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.914 100.107 -1.227
201509 -0.773 100.245 -1.036
201512 -0.677 100.572 -0.904
201603 5.506 101.653 7.277
201606 -0.484 102.267 -0.636
201609 -0.563 102.118 -0.741
201612 0.740 102.614 0.969
201703 -0.516 103.972 -0.667
201706 -0.595 103.902 -0.769
201709 -0.712 104.170 -0.918
201712 -1.281 104.804 -1.642
201803 -0.809 105.419 -1.031
201806 -1.035 106.063 -1.311
201809 -0.108 106.618 -0.136
201812 -1.023 107.252 -1.281
201903 -1.372 107.876 -1.709
201906 -1.371 107.896 -1.707
201909 57.695 107.470 72.124
201912 -2.134 108.065 -2.653
202003 -1.202 108.550 -1.488
202006 -2.351 108.540 -2.910
202009 -3.066 108.441 -3.798
202012 -1.270 108.511 -1.572
202103 -1.943 109.522 -2.383
202106 -1.423 110.305 -1.733
202109 -2.326 111.543 -2.802
202112 -2.845 114.705 -3.332
202203 -1.076 118.620 -1.219
202206 -2.274 120.948 -2.526
202209 -1.955 124.120 -2.116
202212 -3.097 126.578 -3.287
202303 -1.495 126.528 -1.587
202306 -1.977 125.973 -2.108
202309 -1.838 127.083 -1.943
202312 -1.143 128.292 -1.197
202403 -1.954 130.552 -2.011
202406 -2.018 130.691 -2.074
202409 -1.147 130.968 -1.177
202412 -0.988 132.346 -1.003
202503 -0.666 134.348 -0.666

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (WBO:GLPG) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Galapagos NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.